MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
Mayo Clinic Proceedings.
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
Journal of Medical Genetics.